Brian Abrahams
Stock Analyst at RBC Capital
(2.18)
# 2,832
Out of 4,979 analysts
429
Total ratings
42.24%
Success rate
-5.31%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Outperform | $144 → $149 | $144.17 | +3.35% | 22 | Sep 5, 2025 | |
| SION Sionna Therapeutics | Initiates: Sector Perform | $22 | $24.50 | -10.20% | 1 | Sep 3, 2025 | |
| XENE Xenon Pharmaceuticals | Reiterates: Outperform | $55 | $37.51 | +46.63% | 16 | Sep 2, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Outperform | $20 → $19 | $7.91 | +140.20% | 4 | Aug 14, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $60 → $63 | $58.42 | +7.84% | 21 | Aug 8, 2025 | |
| GILD Gilead Sciences | Maintains: Sector Perform | $96 → $98 | $115.76 | -15.34% | 32 | Aug 8, 2025 | |
| ETNB 89bio | Maintains: Sector Perform | $12 → $11 | $8.63 | +27.46% | 15 | Aug 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $39 → $40 | $24.84 | +61.03% | 2 | Aug 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $430 → $405 | $396.48 | +2.15% | 55 | Aug 5, 2025 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $18 → $10 | $8.35 | +19.83% | 11 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $688 → $695 | $556.53 | +24.88% | 33 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $208 → $219 | $143.60 | +52.51% | 39 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $68 → $72 | $85.60 | -15.89% | 22 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $17.64 | +30.39% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $8.08 | +60.89% | 19 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $75 | $62.96 | +19.12% | 1 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $57.00 | +17.54% | 2 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $12.52 | +147.70% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $1.5 | $0.44 | +240.75% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $33 | $6.33 | +421.33% | 12 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $58 | $9.53 | +508.60% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $34.25 | +145.26% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $13.42 | +131.00% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $4 → $3 | $1.75 | +71.43% | 13 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $1.67 | +139.52% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $125.68 | +13.78% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $26.60 | +50.38% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $30 | $32.77 | -8.45% | 11 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $9.77 | +125.18% | 9 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $9.06 | +65.65% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $4.89 | +84.05% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $68.55 | -51.86% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $31.50 | - | 4 | Dec 4, 2017 |
Neurocrine Biosciences
Sep 5, 2025
Maintains: Outperform
Price Target: $144 → $149
Current: $144.17
Upside: +3.35%
Sionna Therapeutics
Sep 3, 2025
Initiates: Sector Perform
Price Target: $22
Current: $24.50
Upside: -10.20%
Xenon Pharmaceuticals
Sep 2, 2025
Reiterates: Outperform
Price Target: $55
Current: $37.51
Upside: +46.63%
Aardvark Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $7.91
Upside: +140.20%
PTC Therapeutics
Aug 8, 2025
Maintains: Outperform
Price Target: $60 → $63
Current: $58.42
Upside: +7.84%
Gilead Sciences
Aug 8, 2025
Maintains: Sector Perform
Price Target: $96 → $98
Current: $115.76
Upside: -15.34%
89bio
Aug 8, 2025
Maintains: Sector Perform
Price Target: $12 → $11
Current: $8.63
Upside: +27.46%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Outperform
Price Target: $39 → $40
Current: $24.84
Upside: +61.03%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $430 → $405
Current: $396.48
Upside: +2.15%
Prothena Corporation
Aug 5, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $8.35
Upside: +19.83%
Aug 4, 2025
Maintains: Sector Perform
Price Target: $688 → $695
Current: $556.53
Upside: +24.88%
Aug 1, 2025
Maintains: Outperform
Price Target: $208 → $219
Current: $143.60
Upside: +52.51%
Jul 30, 2025
Maintains: Sector Perform
Price Target: $68 → $72
Current: $85.60
Upside: -15.89%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $17.64
Upside: +30.39%
Jun 30, 2025
Reiterates: Outperform
Price Target: $13
Current: $8.08
Upside: +60.89%
Jun 24, 2025
Maintains: Outperform
Price Target: $35 → $75
Current: $62.96
Upside: +19.12%
Jun 3, 2025
Reiterates: Outperform
Price Target: $67
Current: $57.00
Upside: +17.54%
May 15, 2025
Reiterates: Outperform
Price Target: $31
Current: $12.52
Upside: +147.70%
May 14, 2025
Reiterates: Sector Perform
Price Target: $1.5
Current: $0.44
Upside: +240.75%
May 13, 2025
Maintains: Outperform
Price Target: $34 → $33
Current: $6.33
Upside: +421.33%
May 7, 2025
Maintains: Outperform
Price Target: $65 → $58
Current: $9.53
Upside: +508.60%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $34.25
Upside: +145.26%
Mar 7, 2025
Initiates: Outperform
Price Target: $31
Current: $13.42
Upside: +131.00%
Mar 4, 2025
Maintains: Sector Perform
Price Target: $4 → $3
Current: $1.75
Upside: +71.43%
Mar 4, 2025
Reiterates: Sector Perform
Price Target: $4
Current: $1.67
Upside: +139.52%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $125.68
Upside: +13.78%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $26.60
Upside: +50.38%
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $32.77
Upside: -8.45%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $9.77
Upside: +125.18%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $9.06
Upside: +65.65%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $4.89
Upside: +84.05%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $68.55
Upside: -51.86%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $31.50
Upside: -